Clinical Trial Search

Primary: Percentage of Participants With Objective Response in the CNS, Assessed Using Response Assessment in Neuro-Oncology-Brain Metastases (RANO-BM) Criteria — 10.8; 0.0…

Primary: Prevalence of Femoroacetabular Impingement (FAI) — 28; 172 Participants

Primary: Change From Baseline in Hemoglobin A1c (HbA1c) Efficacy Estimand at Week 26 — -0.43; -0.38 percentage of HbA1c

Primary: Progression-free Survival — 7.9; 9.0; 8.5 months — p=0.12

Primary: Mean AUC0-last_ss (Test vs. Reference) — 92.884; 62.76666667; 419.97; 260.3 micro/mL/hr

Primary: Percentage of Eyes With Postoperative BCDVA 20/40 Snellen or Better by Study Visit - All HMIOL Cohort — 99.1; 100.0 percentage of eyes

Primary: Percentage of Participants in Stage 1 Achieving hSBA Titer Level Greater Than or Equal to (>=) Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Strains at…

Primary: RRp Arms of Sensor Accuracy — 2.1 respiration per minute (RPM)

Primary: Clinical Outcomes — 5.39; 5.74 Days

Primary: Adverse Effects — 1 Participants

Primary: Change From Baseline in the Test of Variables in Attention-Continuous Performance Test (TOVA-CPT) "D-prime" Standard Score (SS) at Week 12 — 5.2; 4.5 d-prime — p=0.694

Primary: Number of Participants Willing to Assess Their Pain Using Technology — 5; 3 Participants

Primary: Maximum Observed Plasma Concentration (Cmax) of Pimodivir — 5933; 5378 Nanogram per milliliter (ng/mL)

Primary: Change in the Functional MRI Metrics Ktrans Between 2 Weeks and Baseline — 0.026 per minute (or min-1) — p=0.0016

Primary: Number of Participants Who Received CERE-120 Treatment — 3; 3; 24; 27 Participants